27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Regeneron Pharmaceuticals Inc's (NASDAQ:REGN) REGEN-COV.
- The casirivimab and imdevimab antibody cocktail (Ronapreve) was backed by the CHMP for treating adults and children over 12 with COVID-19 who do not require oxygen support and are at high risk of severe disease.
- Related Link: Regeneron-Roche's COVID-19 Treatment Shows Long Term Benefit After Single Dose.
- Regeneron is collaborating with Roche Holdings AG (OTC: RHHBY), primarily responsible for development and distribution outside the U.S.
- Price Action: REGN shares are up 0.77% at $627, RHHBY stock is up 0.18% at $50.32 during the market session on the last check Thursday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!